A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

NCT06745193 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Carcinoma

Interventions

DRUG: chidamide+Camrelizumab+Apatinib
DRUG: Irinotecan or Docetaxel or Paclitaxel

Sponsor

Peking University